Independent Medical Education Grant seeks to support education for healthcare teams caring for patients with mPC (mCSPC and mCRPC) with a focus on targeted therapies, including integration of testing into clinical practice for implementation of guideline-concordant care and optimal patient management.
Donor Name: Pfizer
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 04/28/2026
Size of the Grant: $100,000 to $500,000
Grant Duration: 2 Years
Details:
Area of Interest
Potential applicants are encouraged to identify and address educational gaps relating to optimal application and management of targeted therapies for patients with mPC in diverse clinical practice settings. This may include education related to:
- Guideline concordance and best practices for integration of testing into clinical practice
- Existing and emerging data on the efficacy and safety regarding PARPi’s
- Clinical data regarding PARPi combinations and how to mitigate associated side effects
Funding Information
- The estimated total available budget related to this RFP is $500,000. Individual projects requesting between $5,000 – $250,000 will be considered.
- Maximum project length is 18 months.
Geographic Scope/Location of Project:
United States
Eligibility Criteria
- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions/ organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. They strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit, the requesting organization must be accredited.
Requirements
Primary Area of Interest:
- Oncology – Genitourinary
General Area of Interest for this RFP:
It is not intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
- Guideline concordance and best practices for integration of testing into clinical practice, including: when to order testing and how to interpret results of biomarkers and genetic mutations (inclusive of all HRR mutations, i.e. BRCA and non-BRCA), the role of the multidisciplinary team in ordering
tests, and education on strategies to identify and remove barriers to appropriate testing for patients with prostate cancer. - Existing and emerging data on efficacy and safety regarding PARPi’s used in the treatment of mPC including better understanding of: 1) the mechanism of action and the biological and clinical
rationale for PARPi combinations and; 2) clinical safety, treatment sequencing and patient
subgroup data. Review emerging PARPi data in both mCSPC and mCRPC disease states. Clinical data regarding PARPi combinations and how to mitigate associated side effects for optimal patient care, including but not limited to, the role of the multidisciplinary team in ongoing therapy management. - Best practices for initiating guideline concordant care for patients with mPC in community healthcare settings for optimal therapy management of PARPi combinations in prostate cancer including but not limited to, implementation of genetic testing workflows and encouraging patient engagement in treatment decisions and clinical trial participation.
Target Audience
- Academic and community oncology and urology practitioners, oncology nurses and nurse practitioners, physician assistants, pharmacists, genetic counselors, and other healthcare professionals involved in the care and treatment of patients with mPC.
For more information, visit Pfizer.
